



ASX and Media Release

Anti-cancer activity of CAVATAK™ to be presented at prestigious US cancer conference

- CAVATAK™ oral presentation at AACR conference
- Encouraging activity of CAVATAK™ in injected and metastatic tumours

6 March 2014, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) Principal Investigator Dr Robert Andtbacka will present interim Phase 2 CALM trial data on the activity of CAVATAK™ at the prestigious American Association for Cancer Research (AACR) Conference in April.

In January Viralytics announced that target enrolment was achieved in the US CALM trial when the 54th late stage melanoma patient was injected with CAVATAK™. There is strong interest from oncologists at leading US cancer centres with interim results including 14 of 40 (35%) evaluable patients reaching the six-month immune related progression-free survival¹ (irPFS) target and with 12 of the first 20 patients alive at one year (60%).

The title of Dr Andtbacka's AACR presentation is:

CAVATAK-mediated oncolytic immunotherapy in advanced melanoma patients.

The presentation will focus on CAVATAK's promising activity in non-injected metastatic tumours in a number of patients participating in the CALM study. Examples of significant or complete reduction of metastatic tumours in some patients will be discussed. Such activity is highly suggestive of an anti-cancer immune response in addition to CAVATAK's induced cancer cell lysis and death. This dual mechanism of action is known as oncolytic immunotherapy with anti-cancer activity in tumour cells at the site of injection as well as distant body locations.

The AACR conference will be held in San Diego, California on 5-9 April 2014 with over 17,000 participants expected, including the pharmaceutical industry. A particular focus of the meeting is the most compelling emerging fields of cancer research.

¹ Progression free survival measures the length of time that an individual lives with the cancer without it worsening.

For personal use only



Dr Andtbacka MD, CM, FACS, FRCSC an Associate Professor at the University of Utah-based Huntsman Cancer Institute (HCI) is recognised as a global leader in injectable therapy for melanoma. The HCI is a US National Cancer Institute designated cancer research facility and hospital.

Viralytics Chief Executive Officer Dr Malcolm McColl said: "We are pleased that Dr Andtbacka will present CAVATAK™ data at this prestigious conference. CAVATAK™ continues to generate promising results in melanoma patients and we believe these further reports of CAVATAK™ activity in metastatic cancer will be of interest to the oncology community including potential partners."

The abstract is posted on the AACR website at the address below and can be sourced from our Viralytics webpage.

[Link to AACR Abstract](#)

The full presentation will be available from 7 April, 2014 US time and a link will be provided on the Viralytics website.

Enquiries:

Dr Malcolm McColl
Chief Executive Officer
02 9988 4000

Mr Rudi Michelson
Monsoon Communications
03 9620 3333

About Viralytics Ltd:

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK™'s preferential targeting of cancer cells provides the potential for low toxicity in the patient.

The company has fully enrolled a phase 2 clinical trial of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics has commenced a Phase 1/2 trial of CAVATAK™ delivered systemically (intravenously). This trial, referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study, will enrol patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.

For personal use only